FindTrial
Sign In

CAP-1002

BIOLOGICAL2 trials

Sponsors

Capricor Inc.

Conditions

Covid19Genetic Diseases, InbornGenetic Diseases, X-LinkedMuscular DiseasesMuscular Disorders, AtrophicMuscular DystrophiesMuscular Dystrophy, DuchenneNervous System Diseases

Phase 2

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
CompletedNCT03406780
Capricor Inc.Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Muscular Diseases +5
Start: 2018-04-04End: 2020-03-10Updated: 2025-05-28
Intravenous Infusion of CAP-1002 in Patients With COVID-19
CompletedNCT04623671
Capricor Inc.Covid19
Start: 2020-11-15End: 2022-02-04Updated: 2025-02-20

Related Papers

Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
2022-03-0152 citations